Harris et al., 1997 - Google Patents
Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59Harris et al., 1997
View PDF- Document ID
- 7728587982294886597
- Author
- Harris C
- Kan K
- Stevenson G
- Morgan B
- Publication year
- Publication venue
- Clinical & Experimental Immunology
External Links
Snippet
Immunotherapy using MoAbs is inefficient due to limited activation of human effectors by mouse antibodies and multiple protective mechanisms available to host cells against autologous complement. We have used chemically engineered antibody constructs and …
- 102000004965 antibodies 0 title abstract description 82
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harris et al. | Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59 | |
| US20240084033A1 (en) | Cancer therapy using cldn6 target-directed antibodies in vivo | |
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| EP0712307B1 (en) | Methods for b-cell population control | |
| TWI774238B (en) | Bispecific cd33 and cd3 binding proteins | |
| Tutt et al. | Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors | |
| AU2006326267B2 (en) | Biological materials and uses thereof | |
| EP3312198A1 (en) | Monoclonal anti-gt468 antibodies for treatment of cancer | |
| EA016717B1 (en) | Hyman monoclonal antibody having opsonic phagocytic killing activity against enterococcus and staphylococcus aureus and uses thereof | |
| KR20170122258A (en) | CD20 binding molecules and uses thereof | |
| EP3421499A1 (en) | Monoclonal antibodies for treatment of cancer | |
| Schwartz-Albiez et al. | Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy? | |
| Pedersen et al. | Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement | |
| Matsui et al. | Activation of the alternative pathway of complement by apoptotic Jurkat cells | |
| Inagaki et al. | Expression of the ULBP ligands for NKG2D by B‐NHL cells plays an important role in determining their susceptibility to rituximab‐induced ADCC | |
| Song et al. | Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells | |
| US20220267442A1 (en) | METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY | |
| WO2009002939A2 (en) | Autophilic antibodies | |
| JP2005536199A (en) | Antibodies and their use | |
| CN101300021A (en) | Antibodies and uses thereof | |
| CA2295914A1 (en) | Antibodies and scfv immunotoxins specific to imported fire ants, and their application | |
| Khosravi et al. | Triggering of the immune response to MCF7 cell line using conjugated antibody with bacterial antigens: In-vitro and in-vivo study | |
| Vogel | Complement, a biologic effector mechanism for tumor cell killing | |
| Ohta et al. | Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo | |
| AU2012216655B2 (en) | Biological materials and uses thereof |